{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:58:31Z","timestamp":1767664711274,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00432-022-04185-w","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T04:02:22Z","timestamp":1658462542000},"page":"3075-3080","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7214-4818","authenticated-orcid":false,"given":"Diogo","family":"Martins-Branco","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7864-3637","authenticated-orcid":false,"given":"Guilherme","family":"Nader-Marta","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2203-161X","authenticated-orcid":false,"given":"Ana","family":"Tecic Vuger","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-925X","authenticated-orcid":false,"given":"Veronique","family":"Debien","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5153-1766","authenticated-orcid":false,"given":"Lieveke","family":"Ameye","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-3544","authenticated-orcid":false,"given":"Mariana","family":"Brand\u00e3o","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1162-7963","authenticated-orcid":false,"given":"Kevin","family":"Punie","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2296-9264","authenticated-orcid":false,"given":"Angela","family":"Loizidou","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1150-1295","authenticated-orcid":false,"given":"Karen","family":"Willard-Gallo","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8009-403X","authenticated-orcid":false,"given":"Chloe","family":"Spilleboudt","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7412-9163","authenticated-orcid":false,"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-8504","authenticated-orcid":false,"given":"Martine","family":"Piccart","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4509","authenticated-orcid":false,"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"4185_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/J.EJCA.2021.10.014","volume":"160","author":"A Becerril-Gaitan","year":"2022","unstructured":"Becerril-Gaitan A, Vaca-Cartagena BF, Ferrigno AS et al (2022) Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after coronavirus disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. Eur J Cancer 160:243\u2013260. https:\/\/doi.org\/10.1016\/J.EJCA.2021.10.014","journal-title":"Eur J Cancer"},{"key":"4185_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANNONC.2021.10.014","author":"C Corti","year":"2021","unstructured":"Corti C, Antonarelli G, Scott\u00e9 F et al (2021) Seroconversion rate after vaccination against COVID-19 in patients with cancer\u2014a systematic review. Ann Oncol. https:\/\/doi.org\/10.1016\/J.ANNONC.2021.10.014","journal-title":"Ann Oncol"},{"key":"4185_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4390","author":"N Eliakim-Raz","year":"2021","unstructured":"Eliakim-Raz N, Massarweh A, Stemmer A, Stemmer SM (2021) Durability of response to SARS-CoV-2 BNT162b2 vaccination in patients on active anticancer treatment. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4390","journal-title":"JAMA Oncol"},{"key":"4185_CR4","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0597","author":"C Karacin","year":"2021","unstructured":"Karacin C, Eren T, Zeynelgil E et al (2021) Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Futur Oncol. https:\/\/doi.org\/10.2217\/fon-2021-0597","journal-title":"Futur Oncol"},{"key":"4185_CR5","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1182\/bloodadvances.2021005094","volume":"5","author":"C Perry","year":"2021","unstructured":"Perry C, Luttwak E, Balaban R et al (2021) Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv 5:3053\u20133061. https:\/\/doi.org\/10.1182\/bloodadvances.2021005094","journal-title":"Blood Adv"},{"key":"4185_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejca.2020.08.011","volume":"139","author":"KS Saini","year":"2020","unstructured":"Saini KS, Tagliamento M, Lambertini M et al (2020) Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer 139:43\u201350. https:\/\/doi.org\/10.1016\/j.ejca.2020.08.011","journal-title":"Eur J Cancer"},{"key":"4185_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174480","author":"E Terpos","year":"2021","unstructured":"Terpos E, Gavriatopoulou M, Fotiou D et al (2021) Poor neutralizing antibody responses in 132 patients with cll, nhl and hl after vaccination against sars-cov-2: a prospective study. Cancers (basel). https:\/\/doi.org\/10.3390\/cancers13174480","journal-title":"Cancers (basel)"},{"key":"4185_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/J.EJCA.2021.10.013","volume":"159","author":"S Tran","year":"2021","unstructured":"Tran S, Truong TH, Narendran A (2021) Evaluation of COVID-19 vaccine response in patients with cancer: an interim analysis. Eur J Cancer 159:259\u2013274. https:\/\/doi.org\/10.1016\/J.EJCA.2021.10.013","journal-title":"Eur J Cancer"},{"key":"4185_CR9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1072","author":"I Waldhorn","year":"2021","unstructured":"Waldhorn I, Holland R, Goshen-Lago T et al (2021) Six month efficacy and toxicity profile of BNT162b2 vaccine in cancer patients with solid tumors. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1072","journal-title":"Cancer Discov"},{"key":"4185_CR11","unstructured":"World Health Organization Status of COVID-19 Vaccines within WHO EUL\/PQ evaluation process (2022). https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/documents\/Status_COVID_VAX_23Dec2021.pdf. Accessed 18 Jan 2022"},{"key":"4185_CR10","unstructured":"World Health Organization WHO Coronavirus (COVID-19) Dashboard (2022a). https:\/\/covid19.who.int\/. Accessed 18 Jan 2022"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04185-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04185-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04185-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T12:05:59Z","timestamp":1688213159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04185-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4185"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04185-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"assertion":[{"value":"15 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DMB: Honoraria and advisory board fees from Daiichi Sankyo, Janssen, Pfizer, Merck Sharp and Dohme, Angelini, AstraZeneca, and Novartis, meeting\/travel grants from LEO Farmac\u00eauticos, Merck Sharp and Dohme, Ipsen, Janssen, Roche, Laborat\u00f3rios Vit\u00f3ria, and Novartis, and institutional research grant from F. Hoffmann-La Roche Ltd (all outside the submitted work); GNM: Support to attend medical conferences: Roche and Bayer (all outside the submitted work); ATV: Honoraria and advisory board fees from Roche, Pfizer, Novartis, Astellas, meeting\/travel grants from Roche, Pfizer, Novartis (all outside the submitted work); MB: Meeting\/travel grants from Roche\/GNE, Sanofi and Takeda; speaker fees from Roche\/GNE and Jansen (all outside the submitted work); KP: KP\u2019s institution received speaker fees, honoraria for advisory\/consultancy roles and\/or research funding from AstraZeneca, Eli Lilly, Gilead Sciences, Medscape, MSD, Mundi Pharma, Novartis, Pfizer, Pierre Fabre, Hoffmann\/La Roche, Sanofi, Teva, Vifor Pharma. KP received travel support from AstraZeneca, Novartis, Pfizer, PharmaMar, Hoffmann\/La Roche. K.P. received speaker fees and honoraria for advisory\/consultancy roles from AstraZeneca, Gilead Sciences, Novartis, Roche, Seatlle Genetics (all outside the submitted work); KWG: Speaker fees, honoraria for advisory\/consultancy roles and\/or research funding from BMS,\u00a0Pfizer, Philips and iTeos Therapeutics (all outside the submitted work); AA: Roche, Lilly, Amgen, EISAI, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, AstraZeneca, Bayer, Leo Pharma, Merck, Daiichi, Seattle Genetics, Pierre Fabre (all outside the submitted work); MP: Board Member (Scientific Board) from Oncolytics, consultant (honoraria) from AstraZeneca, Camel-IDS\/Precirix, Gilead, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Pfizer, Roche-Genentech, Seattle Genetics, Immutep, Seagen, NBE Therapeutics, and Frame Therapeutics, and institutional research grants from AstraZeneca, Immunomedics, Lilly, Menarini, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, and Synthon (all outside the submitted work); EdA: Honoraria and\/or advisory board from Roche\/GNE, Novartis, Seattle Genetics, Zodiac, Libbs and Pierre Fabre. Travel grants from Roche\/GNE and GSK\/Novartis. Research grant to my institution from Roche\/GNE, Astra-Zeneca, GSK\/Novartis and Servier (all outside the submitted work). VD, LA, AL, and CS have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}